Table 3.

Possibly or probably treatment-related AEs (occurring in >5% of patients)

	Switch patients (n = 33), n (%)	Other patients (n = 26), n (%)
Patients reporting ≥1 adverse event	18 (55)	24 (92)*
Diarrhea	9 (27)	17 (65)†
Headache	7 (21)	3 (12)
Abdominal pain upper	3 (9)	5 (19)
Abdominal pain	2 (6)	6 (23)
Nausea	4 (12)	4 (15)
Injection site pain	4 (12)	2 (8)
Injection site irritation	2 (6)	3 (12)
Alopecia	1 (3)	3 (12)
Flatulence	2 (6)	2 (8)
Injection site pruritus	1 (3)	3 (12)
Serious adverse event: pancreatitis (resolved)	1 (3)	–

* P = 0.0015 versus switch patients; ^†  P = 0.0034 versus switch patients